CA3057741A1 - Novel crystal forms of a pol1 inhibitor - Google Patents

Novel crystal forms of a pol1 inhibitor Download PDF

Info

Publication number
CA3057741A1
CA3057741A1 CA3057741A CA3057741A CA3057741A1 CA 3057741 A1 CA3057741 A1 CA 3057741A1 CA 3057741 A CA3057741 A CA 3057741A CA 3057741 A CA3057741 A CA 3057741A CA 3057741 A1 CA3057741 A1 CA 3057741A1
Authority
CA
Canada
Prior art keywords
crystalline form
crystalline
degree
compound
depicts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3057741A
Other languages
English (en)
French (fr)
Inventor
Mustapha Haddach
Original Assignee
Pimera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pimera Inc filed Critical Pimera Inc
Publication of CA3057741A1 publication Critical patent/CA3057741A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3057741A 2017-03-28 2018-03-28 Novel crystal forms of a pol1 inhibitor Pending CA3057741A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762477746P 2017-03-28 2017-03-28
US62/477,746 2017-03-28
US201762491635P 2017-04-28 2017-04-28
US62/491,635 2017-04-28
PCT/US2018/024898 WO2018183540A1 (en) 2017-03-28 2018-03-28 Novel crystal forms of a pol1 inhibitor

Publications (1)

Publication Number Publication Date
CA3057741A1 true CA3057741A1 (en) 2018-10-04

Family

ID=63676829

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3057741A Pending CA3057741A1 (en) 2017-03-28 2018-03-28 Novel crystal forms of a pol1 inhibitor

Country Status (7)

Country Link
US (2) US11912706B2 (enExample)
EP (1) EP3601286A4 (enExample)
JP (3) JP2020512975A (enExample)
CN (2) CN115583948A (enExample)
BR (1) BR112019020058A2 (enExample)
CA (1) CA3057741A1 (enExample)
WO (1) WO2018183540A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
US11912706B2 (en) 2017-03-28 2024-02-27 Pimera, Inc. Crystal forms of a POL1 inhibitor

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1042801A (en) 1909-10-28 1912-10-29 Isidor Kitsee Protecting kinematographic films.
NL7709746A (nl) 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
DE19509043A1 (de) 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
ATE319713T1 (de) 2000-10-03 2006-03-15 Bristol Myers Squibb Co Amino- substituierte tetracyclische verbindungen die als entzündungshemmende mittel nützlich sind, und diese enthaltende arzneimittel.
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
KR100944600B1 (ko) 2003-04-07 2010-02-25 사일린 파마슈티칼스, 인크 치환된 퀴노벤족사진 유사체
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
EP1802306A2 (en) 2004-09-17 2007-07-04 Cylene Pharmaceuticals, Inc. Quinolone analog as cell proliferation inhibitors
EP1874731A4 (en) 2005-04-15 2009-08-05 Cylene Pharmaceuticals Inc CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
US7816524B2 (en) 2005-08-05 2010-10-19 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8142909B2 (en) 2006-02-10 2012-03-27 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2008060693A2 (en) 2006-05-17 2008-05-22 Cylene Pharmaceuticals, Inc. Tetracyclic imidazole analogs
CN101888780B (zh) 2007-10-05 2014-08-13 生华生物科技股份有限公司 喹诺酮类似物及其相关方法
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
US8368062B2 (en) 2008-11-03 2013-02-05 Lg Chem, Ltd. Nitrogen-containing heterocyclic compound and organic electronic device using the same
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
KR101567610B1 (ko) 2010-11-04 2015-11-09 주식회사 엘지화학 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자
SG11201400988SA (en) 2011-10-21 2014-07-30 Glaxosmithkline Llc Compounds and methods for enhancing innate immune responses
KR101561730B1 (ko) 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자
WO2015079411A1 (en) 2013-11-28 2015-06-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
US9758518B2 (en) * 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
RS57493B1 (sr) 2014-05-09 2018-10-31 Pimera Inc Novi sastavi, upotrebe i metode za njihovo spravljanje
CN106349244B (zh) * 2015-07-13 2018-07-27 首都医科大学 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl，其合成，活性和应用
CA3005730A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US11912706B2 (en) 2017-03-28 2024-02-27 Pimera, Inc. Crystal forms of a POL1 inhibitor

Also Published As

Publication number Publication date
CN115583948A (zh) 2023-01-10
JP2025060702A (ja) 2025-04-10
US11912706B2 (en) 2024-02-27
EP3601286A1 (en) 2020-02-05
EP3601286A4 (en) 2020-09-23
US20250243200A1 (en) 2025-07-31
WO2018183540A1 (en) 2018-10-04
CN110709400A (zh) 2020-01-17
BR112019020058A2 (pt) 2020-07-14
US20230192694A1 (en) 2023-06-22
JP2020512975A (ja) 2020-04-30
JP2023126708A (ja) 2023-09-08

Similar Documents

Publication Publication Date Title
US20250243200A1 (en) Crystal forms of a pol1 inhibitor
AU2016348847B2 (en) Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor
WO2017219948A1 (en) Crystalline forms of triazolopyrimidine compound
AU2017202145B2 (en) Novel compositions, uses and methods for making them
KR20170068597A (ko) 브로모도메인 저해제
BR112018010118B1 (pt) Inibidores de cxcr2
CA2997768C (en) Salts of n-{(7r)-4-[(3r,4r,5s)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5h-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide used as pim kinase inhibitors
ES3008927T3 (en) Process for preparing modulators of p300 and/or cbp
KR20150142688A (ko) 티로신 키나아제 억제제의 결정질 형태 및 이의 염
KR20180093995A (ko) 푸마길롤 유도체 및 그의 다형체
BR112014001299B1 (pt) Forma cristalina anidra do sal sódico de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil) -fenil]-benzenossulfonamida, composição farmacêutica, seus usos e método para a preparação de uma composição farmacêutica compreendendo a dita forma cristalina
EP4006033A1 (en) Adenosine receptor antagonist
CA3301341A1 (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
US9822467B2 (en) Methods and systems relating to the selection of substrates comprising crystalline templates for the controlled crystallization of molecular species
US9956208B2 (en) Compounds for the treatment of cancer and inflammatory diseases
US9724348B2 (en) Crystalline forms
DK2556063T3 (en) 1-cyclopropyl-8-methyl-7- [5-methyl-6- (methylamino) -3-pyridinyl] -4-oxo-1,4-dihydro-3-QUINOLINCARBOXYLSYRESALTE
HK40020743A (en) Novel crystal forms of a pol1 inhibitor
WO2025024823A1 (en) Salts and solid forms of compounds that modulate ikzf2
EA044976B1 (ru) Кристаллические формы ингибитора фосфоинозитид 3-киназы (pi3k)
AU2022347450A1 (en) Erk5 degraders and uses thereof
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230320

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250506

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250506

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D141 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CONDITIONAL ALLOWANCE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106